Michael Buckley to Return to True Religion Apparel as Chief Executive Officer
12.11.2019 21:30:00 EET | Business Wire | Press release
True Religion Apparel, Inc., announced that the Board of Directors has appointed Michael Buckley as its new Chief Executive Officer, effective immediately. Mr. Buckley was previously President of True Religion Apparel from 2006 to 2010. He will be responsible for developing and implementing the future vision and roadmap for True Religion. Mr. Buckley will report to the Board of Directors of the Company.
Michael Buckley is a leading retail and consumer products executive with over 30 years’ successful industry experience both domestically and internationally in growing brands and creating value. He most recently was Chief Executive Officer of Differential Brands Group (renamed Centric Brands upon the acquisition of Global Brands Group) a NASDAQ publicly traded company. Differential owned the brands Hudson Jeans, Robert Graham and Swims. Prior to Differential, from 2011-2016 he was Chief Executive Officer of Robert Graham Designs until its sale to Differential Brands Group for $180 million. Prior to Robert Graham, from 2006-2010 as President of True Religion Apparel, sales grew from $100 million to over $300 million, EBITDA from $30 million to over $90 million and market cap on NASDAQ tripled to $850 million. The retail platform expanded from 1 to 100 stores, the company expanded its product line to include t-shirts, woven shirts, knit tops, outerwear and a number of licenses including footwear, fragrances, eyewear, swimwear, and accessories. In both 2008 and 2009 True Religion was ranked the #1 most profitable US publicly traded apparel company out of all US publicly traded apparel companies, as measured by after tax profit margin.
Gene Davis, Chairman of the Board stated, “We are extremely excited and proud to welcome Michael Buckley back to True Religion Apparel. He brings years of experience in the men's and women's denim and sportswear arena, including his former role as President of True Religion. Michael has had many accomplishments in the apparel industry over the past thirty+ years and he brings a well-rounded and highly relevant skill set to the True Religion leadership team. We thank Farla Efros for serving True Religion as its Interim CEO over the past six months. We are pleased that she and the HRC Advisory team will continue supporting True Religion over the coming months.”
Commenting on his appointment, Mr. Buckley added, “I am thrilled to return to True Religion and lead the company as its new Chief Executive Officer at this exciting time in the brand's evolution. I look forward to working with the Board of Directors, Farla Efros and HRC Advisory, and the entire True Religion team.”
About True Religion Apparel, Inc.
In 2002, True Religion emerged onto the Los Angeles denim scene by blowing up the construction of the classic five-pocket jean. With its five-needle thread at two-stitch-per-inch process, the True Religion Super T stitch was instantly recognized for style that was unlike any other denim brand in the world. True Religion speaks to the uniqueness found in all of us. The brand is worn by athletes, musicians, and artists globally to express their individual style. Delivering an exclusive assortment of iconic styles, True Religion Brand Jeans focuses on producing high quality premium denim and sportwear for men’s, women’s and kids.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005825/en/
Contact information
For True Religion:
Carol Moniz
michele marie pr
1261 Broadway, Suite 802
New York, NY 10001
O: 646.863.3923
E: carol@michelemariepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 06:00:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth needed to guide investment, refine product positioning, and identify the features that mattered most in eac
KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release
Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
